Researcher Profile

Susan Goodin, PharmD

Executive Director, Statewide Affairs, CINJ
Professor of Medicine, Medical Oncology
Robert Wood Johnson Medical School
Rutgers, The State University of New Jersey

Rutgers Cancer Institute of New Jersey
195 Little Albany Street
New Brunswick, NJ 08901-1914

Phone: (732) 235-6783
Email: goodin@cinj.rutgers.edu

Assistant: Jennifer Schwager
(732) 235-8064
Email: schwagja@cinj.rutgers.edu

Research Program Alignments

Membership Type: Full


Research Interests

  • Clinical research trials
  • Clinical pharmacology
  • Pharmacokinetics
  • Supportive care
  • Drug interactions

Selected Publications

Stein MN, Goodin S, DiPaola RS. Abiraterone in Prostate Cancer: a new angle to an old problem. Clin Cancer Res 2012, Online First, March 26, 2012.

Goodin S, Griffith N, Chen B, Chuk K, Daouphars M, Doreau C, Pater RA, Schwartz R, Tames MJ, Terkioa R, Vadnais B, Wright D, Meir K. Safe handling of oral chemotherapeutic agents in clinical practice: recommendations from an international pharmacy panel. J Oncol Practice 2011; 7(1):7-12.

Suh DC, Powers CA, Barone JA, Shin H, Kwon J, Goodin S. Full costs of dispensing and administering fluorouracil chemotherapy for outpatients: a microcosting study. Res Social Adm Pharm 2010 Sep; 6(3):246-256.

Stein M, Dvorzhinski D, Goudner M, Bray K, Eddy S, Goodin S, White E, DiPaola RS. Targeting tumor metabolism with 2-deoxyglucose in patients with castrate resistant prostate cancer and advanced malignancies. Prostate 2010; 70(13):1388-94. PMID: 20687211

Medina PJ, Goodin S. Lapatinib: A review of the dual inhibitor of epidermal growth factor receptor tyrosine kinase. Clinical Therapeutics 2008 August, 30 (8):1426-1447. PMID: 18803986

Goodin S, Shih WJ, Kane MP, Medina P, Lambert GH, Gallo M, DiPaola RS. Clinical and biological activity of soy protein powder supplementation in healthy male volunteers. Cancer Epidemiol Biomarkers and Prevention 2007; April 16(4):829-33. PMID: 17416779

Tan AR, Moore DF, Hidalgo M, Doroshow JH, Poplin EA, Goodin S, Mauro D, Rubin EH. Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors. Clin Cancer Res 2006; 12(21):6517-6522. PMID 17065274

Goodin S. Erlotinib: Optimizing Therapy with Predictors of Response? Clin Cancer Res 2006;12(10):2961-2963. PMID 16707589

Blower P, de Wit R, Goodin S, Aapro M. Drug-drug interactions in oncology: why are they important and can they be minimized? Crit Rev in Oncol Hematol 2005;55:117-142. PMID 15890526

Goodin S, Rao K, Kane M, Capanna T, Engle E, Ciardella M, Todd M, DiPaola, RS. A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer with and without prior chemotherapy. Cancer Chemother Pharmacol 2005;56:199-204. PMID: 15838657

Goodin S, Medina P, Capanna T, Winnie J, Shih J, Abrams S, Doyle-Lindrud S, Rao KV, Todd MB, DiPaola RS. Effect of docetaxel in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancer. J Clin Oncol 2005; 23(15):3352-3357. PMID: 157838531

Rao K, Goodin S, Levitt MJ, Dave’ N, Shih WJ, Lin Y, Capanna T, Doyle-Lindrud S, Todd MB, DiPaola RS. A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer. Prostate 2005;62(2)115-122. PMID: 17416779

Kumar P, Perrotti M, Weiss, R, Todd M, Goodin S, Cummings K, DiPaola R. Phase I trial evaluating the maximally tolerated dose of weekly docetaxel with concurrent 3-D conformal radiation therapy in the treatment of localized unfavorable adenocarcinoma of the prostate. J Clin Oncol 2004;22(10):1909-1915. PMID: 15143084

Goodin S, Kane M, Rubin EH. Epothilones: Mechanism of action and biological activity. J Clin Oncol. 2004; 22(10):2015-2025. PMID: 15143095

DiPaola RS, Rinehart J, Nemunitis J, Ebinghaus S, Rubin E, Capanna T, Ciardell M, Doyle-Lindred S, Goodin S, Fontaine M, Adams N, Williams A, Schwartz M, Winchell G, Wickersham K, Deutsch P, Yao S-L. Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer. J Clin Oncol 2002;20 (7);1874-1879. PMID: 11919247

The content for this Research Profile is maintained by Paul Novembre (novembre@cinj.rutgers.edu)